Viridian Therapeutics (VRDN) on Saturday launched its first commercial product, Lumvoa, soon after the U.S. FDA approved the intravenous therapy for thyroid eye disease, a rare autoimmune disease characterized by ocular symptoms such as bulging eyes.
The approval came nearly